Research studies in France and Germany revealed serious health risks faced by diabetes patients prescribed the medication Actos. The respective European countries banned sales of the drug shortly after the report was released. A 10 year research study undertaken by the FDA showed similar findings as the European studies. The study prompted the FDA to issue a safety warning and to advise physicians to discontinue prescribing the medication to any patients with a family history of bladder cancer.
Actos patients and physicians have been advised by the FDA to be vigilant of any signs that bladder cancer may be developing. Patients should make an appointment to see their doctor immediately if they exhibit any of the following symptoms of bladder cancer:
- Blood in the urine
- Pain while urinating
- Lower back or stomach pain
- Urge to urinate frequently
The FDA is actively encouraging Actos or pioglitazone patients to come forward and report any adverse health effects they may have endured through the FDA MedWatch program. Takeda Pharmacueticals, the company responsible for developing and marketing Actos has included members of the Kaiser Permanente Northern California health plan in their ongoing research study. This information will be a critical part of the FDA data evaluation and may determine whether or not Actos remains on the market in the United States.
Actos bladder cancer lawsuits may be filed by patients who fall victim to health complications as a result of taking the medication. It is always in your best interest to consult an experienced and qualified Actos bladder cancer lawyer to determine if you have a valid injury claim and to ensure your legal rights are protected.